Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

PsoBest - The German Psoriasis Registry

Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.

Who May Be Eligible (Plain English)

Who May Qualify: - patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist - age ≥ 18 years - being administered a specific systemic drug for the first time - willing to sign a consent form to participate - sufficient language skills (German) Who Should NOT Join This Trial: - lack of willing to sign a consent form - patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist * age ≥ 18 years * being administered a specific systemic drug for the first time * informed consent to participate * sufficient language skills (German) Exclusion criteria: * lack of informed consent * patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)

Locations (1)

Nationwide group of dermatological centers, hospitals and medical offices
Hamburg, Germany